BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Recipharm AB Secures Financing for Future Growth


5/23/2012 9:08:20 AM

22 May 2012: Recipharm, the international pharmaceutical contract development and manufacturing organisation, today announced it has arranged a five-year loan facility with Swedbank AB (publ), one of the largest banks in Sweden. The total loan facility of Euro 90 million will serve as an additional resource to facilitate future expansion plans set in place for the business, especially in the field of contract pharmaceutical development. The funds will in part be targeted at increasing capital investment into Recipharm’s existing sites and facilities to meet expanding customer demand. The finance will also be used to bolster the next phase of the company’s rolled out programme of strategic acquisitions. Moroever, significant resources from the loan pool will be assigned to building and enhancing existing and new customer relationships.

Thomas Eldered, CEO of Recipham AB, commented: “The new financing will serve to bolster initiatives designed to build and foster strong customer relationships with all our clients across the pharmaceuticals sector. Indeed, Recipharm adopts a partnering approach to client relations to ensure that we consistently provide bespoke services that meet the precise needs of each individual customer both now and in the future. As a forward looking enterprise, we very much want to be there for the long term whilst at the same time having the flexible and established capabilities to respond rapidly to varying and immediate customer needs. Our programme of strategic acquisitions and investment in current facilities has always been geared towards increasing and expanding the services that we tailor to each specific client. We look forward to continuing in this vein.”

About Recipharm

Recipharm AB is a leading contract development and manufacturing organization

(CDMO) based in Sweden employing some 1700 employees. The Company= operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms that include solid dose, granulates and powders, sterile liquids and lyophilisates, semi solids, beta-lactams, hormones, oral liquids, sprays and dry powder inhalers. For more information visit; www.recipharm.com

Contact information

Recipharm – Björn Westberg EVP CFO, + 46 8 602 52 00

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on:

E-mail: t.jervis@defacto.com or a.heeley@defacto.com

Tel: +44 (0) 207 861 3019/3043



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES